Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial

被引：0
|
作者：
Taieb, Julien
Prager, Gerald W.
Fakih, Marwan
Ciardello, Fortunato
Van Cutsem, Eric
Elez, Elena
Cruz, Felipe Melo
Wyrwicz, Lucjan
Stroyakovskiy, Daniil
Papai, Zsuzsanna
Poureau, Pierre-Guillaume
Liposits, Gabor
Cremolini, Chiara
Bondarenko, Igor
Modest, Dominik Paul
Amellal, Nadia
Hassan, Hasnaa
Skanji, Donia
Tabernero, Josep
机构：
[1] Paris Cite Univ, Paris, France
[2] Med Univ Vienna, Vienna, Austria
[3] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[4] Univ Campania Luigi Vanvitelli, Naples, Italy
[5] Univ Hosp Gasthuisberg Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium
[6] Katholieke Univ Leuven, Leuven, Belgium
[7] Vall Hebron Univ Hosp, Barcelona, Spain
[8] Nucl Pesquisa Ensino Rede Sao Camilo, Sao Paulo, Brazil
[9] Maria Sklodowska Curie Natl Canc Res Inst, Dept Radiotherapy & Oncol, Warsaw, Poland
[10] Moscow City Oncol Hosp 62, Moscow, Russia
[11] Hungarian Def Forces Med Ctr, Dept Oncol, Budapest, Hungary
[12] Univ Hosp, Dept Oncol, Brest, France
[13] Reg Hosp West Jutland, Herning, Denmark
[14] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[15] Univ Pisana, Unit Med Oncol 2, Azienda Osped, Pisa, Italy
[16] Dnipro State Med Univ, Dnipro, Ukraine
[17] Charite Univ Med Berlin, Dept Med Hematol Oncol & Canc Immunol, Berlin, Germany
[18] Servier Int Res Inst, Suresnes, France
[19] Vall Hebron Univ Hosp, Barcelona, Spain
[20] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Yuan, Chengbo
    Kurtinecz, Milena
    Pan, Xiaoyun
    Vassilev, Zdravko
    Pisa, Federica
    Ostojic, Helene
    CANCERS, 2025, 17 (06)
  • [22] Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study
    Yamazaki, K.
    Taniguchi, H.
    Masuishi, T.
    Kawakami, T.
    Onozawa, Y.
    Honda, K.
    Tsushima, T.
    Hamauchi, S.
    Mori, K.
    Yasui, H.
    Muro, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S283 - S283
  • [23] Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
    Chida, Keigo
    Kotani, Daisuke
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shitara, Kohei
    Kojima, Takashi
    Taniguchi, Hiroya
    Watanabe, Jun
    Endo, Itaru
    Yoshino, Takayuki
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [24] Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Narita, Yukiya
    Tsushima, Takahiro
    Ishihara, Makoto
    Todaka, Akiko
    Tanaka, Tsutomu
    Yokota, Tomoya
    Kadowaki, Shigenori
    Machida, Nozomu
    Ura, Takashi
    Fukutomi, Akira
    Ando, Masashi
    Onozawa, Yusuke
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Mori, Keita
    Yamazaki, Kentaro
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E15 - E22
  • [25] Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
    Koper, Agnieszka
    Wilenski, Slawomir
    Sledzinska, Paulina
    Bebyn, Marek
    Koper, Krzysztof
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10867 - 10877
  • [26] Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 62 - 62
  • [27] Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
    Agnieszka Koper
    Sławomir Wileński
    Paulina Śledzińska
    Marek Bebyn
    Krzysztof Koper
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10867 - 10877
  • [28] A multicenter exploratory analysis of the possible predictive factors for trifluridine/tipiracil in refractory metastatic colorectal cancer
    Prejac, J.
    Omrcen, T.
    Radic, J.
    Vrdoljak, E.
    Frobe, A.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S316 - S316
  • [29] Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
    Kamiimabeppu, Daisaku
    Osumi, Hiroki
    Shinozaki, Eiji
    Ooki, Akira
    Wakatsuki, Takeru
    Yoshino, Koichiro
    Sato, Taro
    Nakayama, Izuma
    Ogura, Mariko
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [30] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    BMC CANCER, 2019, 19 (01)
12345